Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 177,209 shares, an increase of 469.8% from the May 31st total of 31,099 shares. Currently, 18.2% of the shares of the company are sold short. Based on an average trading volume of 6,889,317 shares, the days-to-cover ratio is currently 0.0 days.

Bluejay Diagnostics Stock Down 11.5%

NASDAQ BJDX traded down $0.38 during trading hours on Friday, hitting $2.93. The company had a trading volume of 56,470 shares, compared to its average volume of 4,000,328. The firm has a market cap of $3.02 million, a P/E ratio of -0.25 and a beta of 0.82. Bluejay Diagnostics has a fifty-two week low of $1.62 and a fifty-two week high of $16.68. The business has a fifty day simple moving average of $2.82 and a 200-day simple moving average of $2.69.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Institutional investors own 18.47% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.